Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP753473.RAVGghZlCgiNu-J-LfIVPvNrhm0dLiwodhZBGVJSlvpGU130_provenance.
• NP752155.RAR9NNke_RVz4EHGGOBNeqw6lVfV0HD105HXegSRFoKcI130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP752155.RAR9NNke_RVz4EHGGOBNeqw6lVfV0HD105HXegSRFoKcI130_provenance.
• assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP271216.RAp2WWTvQWbvml0-KgJy8ogV42nzsfI8x0ugOIpCfCobo130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP271216.RAp2WWTvQWbvml0-KgJy8ogV42nzsfI8x0ugOIpCfCobo130_provenance.
• NP1187332.RAWFO9cYbFyB-wXBktoSMPhpOaE-F-etEs24RySoXYHyc130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1187332.RAWFO9cYbFyB-wXBktoSMPhpOaE-F-etEs24RySoXYHyc130_provenance.
• NP749608.RApbs-ZzGdCKAJPthY3PgNA0RFvid4WncsAslgt7Kbtpw130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749608.RApbs-ZzGdCKAJPthY3PgNA0RFvid4WncsAslgt7Kbtpw130_provenance.
• NP1187327.RAuyZUz8eUvBDH0r092Uo7h-AmONKr9hPF4SPb6ntsMHE130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1187327.RAuyZUz8eUvBDH0r092Uo7h-AmONKr9hPF4SPb6ntsMHE130_provenance.
• NP1187337.RA5Lv5JNPHRt36jIW-u42pAvEXahuV0fgsCIbDP2J4plQ130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1187337.RA5Lv5JNPHRt36jIW-u42pAvEXahuV0fgsCIbDP2J4plQ130_provenance.
• NP1187339.RA3GEhlHzPirsdee2IHKc8lDbo0SRaMMm9eysrg5dEYsk130_assertion description "[Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1187339.RA3GEhlHzPirsdee2IHKc8lDbo0SRaMMm9eysrg5dEYsk130_provenance.